Discovery and optimizing polycyclic pyridone compounds as anti-HBV agents.

Area of Science:

• Medicinal Chemistry
• Hepatitis B Research
• Drug Discovery

Background:

• Hepatitis B virus (HBV) affects 257 million globally, causing chronic liver disease, cirrhosis, and cancer.
• Current treatments lack sufficient efficacy, necessitating novel drug candidates with improved mechanisms of action.
• There is an urgent need for safe and effective therapies to combat the significant global health burden of HBV.

Purpose of the Study:

• To provide an overview of polycyclic pyridone-related anti-HBV agent patents from 2016-2018.
• To discuss current trends and future perspectives in the development of HBV inhibitors.
• To highlight the role of medicinal chemistry approaches in discovering novel HBV therapeutics.

Main Methods:

• Review of patent literature on polycyclic pyridone-related anti-HBV agents.
• Analysis of drug discovery and development strategies, including high-throughput screening (HTS) and hit-to-lead optimization (H2L).
• Exploration of bioisosteric replacement and scaffold hopping techniques.

Main Results:

• Identified significant patent activity in polycyclic pyridone-related anti-HBV agents between 2016 and 2018.
• Demonstrated the growing interest in targeting host factors for HBV inhibition.
• Highlighted the importance of advanced medicinal chemistry techniques in advancing HBV drug development.

Conclusions:

• Medicinal chemistry tools like HTS, H2L, bioisosteric replacement, and scaffold hopping are crucial for HBV inhibitor discovery.
• Polycyclic pyridone-related agents targeting host factors represent a promising area for HBV therapeutic development.
• Continued research and patent innovation are vital for addressing the global challenge of Hepatitis B.